Bruce & Co. Inc. Has $5.17 Million Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Bruce & Co. Inc. boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 21.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,895 shares during the quarter. Supernus Pharmaceuticals makes up approximately 1.5% of Bruce & Co. Inc.’s holdings, making the stock its 24th biggest holding. Bruce & Co. Inc.’s holdings in Supernus Pharmaceuticals were worth $5,169,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares in the last quarter. Torren Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $49,000. Hantz Financial Services Inc. raised its position in Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 458 shares during the last quarter. Global Retirement Partners LLC raised its position in Supernus Pharmaceuticals by 532.4% in the 4th quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 1,182 shares during the last quarter. Finally, Vestcor Inc acquired a new position in Supernus Pharmaceuticals during the 3rd quarter worth $67,000.

Analysts Set New Price Targets

Several research firms have recently commented on SUPN. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Up 0.5%

SUPN stock opened at $47.19 on Friday. Supernus Pharmaceuticals, Inc. has a twelve month low of $32.51 and a twelve month high of $59.68. The company has a market cap of $2.74 billion, a P/E ratio of -92.53, a price-to-earnings-growth ratio of 1.00 and a beta of 0.54. The business’s fifty day moving average is $46.55 and its 200-day moving average is $49.27.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.